Trials / Completed
CompletedNCT02403635
Drug-Drug Interaction Study: ASP2151 and Midazolam
A Single-centre, Open-label Study in Healthy Men to Investigate the Effect of Repeated Oral Doses of ASP2151 on the Pharmacokinetics of Midazolam in Healthy Men
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 27 (actual)
- Sponsor
- Maruho Europe Limited · Industry
- Sex
- Male
- Age
- 18 Years – 45 Years
- Healthy volunteers
- Accepted
Summary
CYP3A4 is involved in the metabolism of many drugs. So, it is important to assess in vivo the induction effect of ASP2151 on that enzyme to determine the extent of any possible drug interactions. The aim of this trial is to investigate the potential for interaction of ASP2151 with the CYP3A4 probe substrate midazolam.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Midazolam | |
| DRUG | ASP2151 |
Timeline
- Start date
- 2015-04-01
- Primary completion
- 2015-05-01
- Completion
- 2015-05-01
- First posted
- 2015-03-31
- Last updated
- 2019-02-21
- Results posted
- 2019-01-14
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT02403635. Inclusion in this directory is not an endorsement.